Celavie Biosciences

Celavet Animal Health

Regenerative Stem Cell Therapy Pioneer, Celavie Biosciences, LLC, to Attend Cell & Gene Meeting on the Mesa on October 2 – 4 in Carlsbad, California

OXNARD, CA – October 1, 2019 

Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, announced today their attendance at the Alliance of Regenerative Medicine’s (ARM) Cell & Gene Meeting on the Mesa to be held October 2nd – 4th in Carlsbad, California. 

Celavet Characterization of Cells Accepted by Center for Veterinary Medicine

Novel cells offer functional and structural restoration advantages for transplantation and therapy

OXNARD, Calif., February 21, 2017—Veterinary regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, received approval from the Center for Veterinary Medicine (CVM) for product characterization of its equine OK100 stem cells. Celavet’s donor selection criteria were approved by the CVM last August. These approvals mark significant progress towards pivotal studies for the OK100 stem cells, proposed to treat tendinitis (e.g., tendon injuries, bowed tendons, etc.) in horses.

PARKINSON’S Highlights – Recent Data

Celavie has targeted Parkinson’s disease (PD) as the first human application of its stem cells (OK99). Parkinson’s disease (PD) is a chronic and progressive movement disorder, meaning that symptoms continue and worsen over time. Nearly one million people in the US are living with Parkinson’s disease. The risk of developing Parkinson’s is about 1 percent at age 60. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms.

Celavie Biosciences Adds Strategic Business Development Team to Bring Novel Stem Cell Technology to Market

OXNARD, Calif., Sept. 22, 2016Celavie Biosciences LLC welcomed a team of leaders in market strategy, medical technology, pharmaceutical R&D, regulations, and product commercialization to help bring their novel stem cell technology to market. Celavie is working on stem cell-based regenerative therapies for the treatment of Parkinson’s disease and other disorders of the central nervous system (CNS), for which there are no long-term treatments or cures.

Celavie Biosciences Awarded U.S. Patents for Stem Cell Technology with Applications for Central Nervous System Disorders

Novel cells offer functional and structural restoration advantages for transplantation and therapy

OXNARD, Calif., September 13, 2016—Regenerative medicine company Celavie Biosciences LLC, announced that the U.S. Patent and Trademark Office issued patents for its pluripotent stem cells with applications for a range of disorders of the central nervous system (CNS), including Parkinson’s disease.

Celavet Equine Donor Selection Criteria Accepted by Center for Veterinary Medicine

CVM approval moves novel stem cell therapy one step closer to restoring health and mobility in horses

OXNARD, Calif., Aug. 12, 2016—Veterinary regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, received approval from the Center for Veterinary Medicine (CVM) for the donor selection criteria of its equine OK100 stem cells. The Investigational New Animal Drug (INAD) file for the OK100 stem cells is proposed to treat tendinitis (e.g., tendon injuries, bowed tendons, etc.) in horses.

Celavie Biosciences Conducts First Clinical Trial for New Stem Cell Treatment

New stem cell technology offers potential to revolutionize regenerative medicine

OXNARD, Calif., Dec. 14, 2015—Regenerative medicine start-up Celavie Biosciences LLC has conducted its first clinical trial to evaluate the safety of their stem cells in treating eight patients suffering from Parkinson’s disease (PD). Seven of the eight patients completed first-year follow-up. No lasting adverse effects or complications over period of more than two years were observed.

Multicenter Open Label Study Investigates Treatment of Equine Tendon Injuries with Novel Stem Cells

Regenerative medicine start-up studies over 400 horses with tendon and ligament injuries

OXNARD, Calif., December 15, 2013—Veterinary regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, successfully completed a multicenter, open label study investigating the treatment of equine tendon and ligament injuries with Celavet’s OK100 stem cells on more than 400 horses.

Innovative Stem Cell Technology Heals Abused Pit Bull “Bernie”

Regenerative medicine start-up granted compassionate use by CVM to aid animal with severe burns

OXNARD, Calif., Aug. 31, 2011—Veterinary regenerative medicine start-up Celavet Inc., a subsidiary of Celavie Biosciences LLC, provided the undifferentiated stem cells successfully used for the treatment of a pit bull with severe burns. Collaborators Dr. Boyd Wagner of Wyomissing Animal Hospital and Dr. Oleg Kopyov of Celavet administered the treatment using a new stem cell technology and a newly created protocol, which resulted in near-total restoration of damaged tissue.

Innovative Stem Cell Technology Shows Promise in Treatment of Equine Tendon Injuries

Unique pluripotent stem cells show favorable structural improvements to damaged tendons

OXNARD, Calif., March 3, 2010—A recent study from Celavet Inc., a subsidiary of Celavie Biosciences LLC, demonstrates promising indications for the efficacy of pluripotent stem cells in the treatment of tendon injuries in horses. Conducted at Cornell University’s College of Veterinary Medicine by Dr. Alan Nixon, the equine study investigates the effect of Celavet’s undifferentiated stem cells versus placebo controls in acute tendonitis lesions in horses’ superficial flexor tendons.

Contact Celavie Biosciences

Changing the Paradigm of Regenerative Medicine and Stem Cell Technology